<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04559854</url>
  </required_header>
  <id_info>
    <org_study_id>20181004</org_study_id>
    <nct_id>NCT04559854</nct_id>
  </id_info>
  <brief_title>Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer</brief_title>
  <acronym>MAC</acronym>
  <official_title>Mindful After Cancer Study: Fostering Positive Body Image, Sexual Health, and Well-being</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to&#xD;
      help women manage their sexual and body image concerns after cancer (Mindful After Cancer,&#xD;
      MAC) to a videoconference format and 2) assess the feasibility, acceptability, and&#xD;
      preliminary effects of the program among breast and gynecologic cancer survivors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims are: 1) Assess the feasibility of the MAC program when delivered via&#xD;
      videoconference and 2) Assess preliminary effects of the the program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility/ Enrollment</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of participants enrolled, Proportion of participants enrolled of those eligible</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility/ Retention in Study</measure>
    <time_frame>1 month post-intervention</time_frame>
    <description>Number and proportion of participants completing all assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility/ Retention in the Program</measure>
    <time_frame>1 month post-intervention</time_frame>
    <description>Mean number of sessions attended, Proportion of participants attending at least 6 of 8 sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability</measure>
    <time_frame>1 month post-intervention</time_frame>
    <description>Endorsement of 10 items characterizing acceptability (e.g., the program met my expectations). Range 10-100. Higher score indicates better acceptability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline self-efficacy at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Self-efficacy for Managing Chronic Disease Scale (adapted). 6 items. Range 6-60. Higher score indicates better self-efficacy for managing sexual health after cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body image at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Body Image Scale. 10 items. Range 0-30. Higher score indicates poorer body image.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline body appreciation at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Body Appreciation Scale. 13 items. Range 13-65. Higher score indicates more positive body appreciation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline anxiety at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>PROMIS Emotional Distress Anxiety Short Form 6a. 6 items. Range 6-30. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates greater anxiety symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline depression at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Center for Epidemiologic Studies Depression Scale (CES-D). 20 items. Range 0-60. Higher score indicates greater depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in facets of baseline mindfulness at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Five-Facet Mindfulness Questionnaire (FFMQ-15). 15 items with 5 sub-scales: Observe, Describe; Act with Awareness; Non-Judgement, Non-Reactivity. Sub-scale score range 3-15. Higher score indicates greater mindfulness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline self-compassion at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Self-Compassion Scale short form. 12 items. Range 12-60. Higher score indicates greater self-compassion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline relationship quality at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>Dyadic Adjustment Scale short form (DAS-7). Range 0-36. Higher score indicates more positive relationship quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline interest in sexual activity at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>PROMIS SexFS 2.0. 2 items. Range 2-10. Raw scores are translated to a T score following PROMIS guidelines. Higher score indicates more interest in sexual activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from satisfaction with sex life at 1 month</measure>
    <time_frame>Baseline and 1 month post-intervention</time_frame>
    <description>New Sexual Satisfaction Scale- Short Form (NSSS-S). 12 items. Range 12-60. Higher score indicates more sexual satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Mindful After Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to attend 8 weekly sessions via videoconference, and to complete home activities and mindfulness practice between sessions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindful After Cancer</intervention_name>
    <description>The intervention includes eight weekly sessions (1.5-2 hours each), plus participant educational materials and audio recorded meditations, and is delivered to women in their homes via group videoconference led by a trained facilitator. Participants are asked to complete activities and mindfulness practice between sessions.</description>
    <arm_group_label>Mindful After Cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of breast or gynecologic cancer at least one year prior to enrollment&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
          -  Have access to a computer, smart phone, or tablet with internet access&#xD;
&#xD;
          -  Ability to spend 15-30 minutes per day on program activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Stage 0 (carcinoma in situ)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica R Gorman, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon State University</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

